213 related articles for article (PubMed ID: 32374509)
1. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
2. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
3. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
4. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
[TBL] [Abstract][Full Text] [Related]
7. Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.
Hensley PJ; Zetter D; Horbinski CM; Strup SE; Kyprianou N
Hum Pathol; 2016 Nov; 57():68-77. PubMed ID: 27402302
[TBL] [Abstract][Full Text] [Related]
8. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
10. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
11. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
12. Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
Eckstein M; Matek C; Wagner P; Erber R; Büttner-Herold M; Wild PJ; Taubert H; Wach S; Sikic D; Wullich B; Geppert CI; Compérat EM; Lopez-Beltran A; Montironi R; Cheng L; van der Kwast T; Colecchia M; van Rhijn BWG; Amin MB; Netto GJ; Lehmann J; Stöckle M; Junker K; Hartmann A; Bertz S
Eur Urol Oncol; 2024 Feb; 7(1):128-138. PubMed ID: 37562993
[TBL] [Abstract][Full Text] [Related]
13. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
Singh R; Singh UP; Agrawal V; Garg M
Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
[TBL] [Abstract][Full Text] [Related]
15. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
16. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.
Tripathi K; Maurya N; Goel A; Singhai A; Garg M
Mol Cell Biochem; 2023 Jun; 478(6):1169-1190. PubMed ID: 36239855
[TBL] [Abstract][Full Text] [Related]
18. Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer.
Compérat E
Eur Urol; 2020 Nov; 78(5):764. PubMed ID: 32631743
[No Abstract] [Full Text] [Related]
19. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
[TBL] [Abstract][Full Text] [Related]
20. Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.
Lobo J; Monteiro-Reis S; Guimarães-Teixeira C; Lopes P; Carneiro I; Jerónimo C; Henrique R
J Transl Med; 2020 Aug; 18(1):303. PubMed ID: 32758253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
